Cancer Family
Neck Neoplasm
CI-CAN-00000283Explore in graph →
Non-malignant634 active trials11 approved drugs67 evidence items
- NCIt
- C3260
Loading cancer entity…
Cancer Family
CI-CAN-00000283Explore in graph →
Clinical trials
2,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06589804 | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | recruiting | Phase 3 | 158 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06475989 | Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer | recruiting | Phase 3 | 264 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 24, 2026 |
| NCT06629597 | A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301) | active not recruiting | Phase 3 | 400 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07177443 | Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma | recruiting | Phase 3 | 710 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07783321 | A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) | not yet recruiting | Phase 3 | 404 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04255849 | Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV | active not recruiting | Phase 3 | 700 | Weill Medical College of Cornell UniversityOTHER | 3 | Sep 14, 2026 | clinicaltrials |
| NCT05721755 | Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck | active not recruiting | Phase 3 | 290 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02135042 | Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA | active not recruiting | Phase 2 / Phase 3 | 924 | NRG OncologyOTHER | 8 | Sep 10, 2026 | clinicaltrials |
| NCT06790966 | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma(VERSATILE-003) | terminated | Phase 3 | 12 | PDS Biotechnology Corp.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT01810913 | Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | suspended | Phase 2 / Phase 3 | 613 | National Cancer Institute (NCI)NIH | 3 | Sep 1, 2026 | clinicaltrials |
| NCT07796789 | Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma | recruiting | Phase 3 | 204 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06976190 | A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(Magic-C002) | recruiting | Phase 3 | 446 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07768189 | A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma(TEMPO-1) | not yet recruiting | Phase 3 | 260 | Corbus Pharmaceuticals Inc.INDUSTRY | 3 | Aug 31, 2026 | clinicaltrials |
| NCT00588770 | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 3 | 403 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT03258554 | Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin | completed | Phase 2 / Phase 3 | 196 | National Cancer Institute (NCI)NIH | 2 | Aug 27, 2026 | clinicaltrials |
| NCT07201337 | Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma. | active not recruiting | Phase 3 | 700 | Sun Yat-sen UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04456322 | Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 381 | Sun Yat-sen UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04178174 | Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer(SHORT-OPC) | recruiting | Phase 3 | 360 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT01893307 | Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer | active not recruiting | Phase 3 | 440 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT00162708 | Very Intense Radiotherapy-chemotherapy Regimen in Advanced HNSCC | completed | Phase 2 / Phase 3 | 120 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07441681 | Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin | recruiting | Phase 3 | 454 | NRG OncologyOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06712888 | Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma(Navigation) | active not recruiting | Phase 3 | 466 | Sun Yat-sen UniversityOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05979961 | Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 464 | Sun Yat-sen UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05063552 | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers | active not recruiting | Phase 2 / Phase 3 | 430 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06854510 | Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma. | active not recruiting | Phase 2 / Phase 3 | 196 | Sun Yat-sen UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07706985 | Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 566 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07705243 | Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma | recruiting | Phase 3 | 86 | Sun Yat-sen UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05451004 | SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer(SELECT) | recruiting | Phase 3 | 510 | Canadian Cancer Trials GroupNETWORK | 2 | Jul 14, 2026 | clinicaltrials |
| NCT03952585 | De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer | active not recruiting | Phase 2 / Phase 3 | 384 | National Cancer Institute (NCI)NIH | 2 | Jul 2, 2026 | clinicaltrials |
| NCT04290663 | Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up(INTERMEDIATE) | recruiting | Phase 3 | 368 | Centre Francois BaclesseOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05050162 | Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer | suspended | Phase 2 / Phase 3 | 1,714 | NRG OncologyOTHER | 5 | Jun 25, 2026 | clinicaltrials |
| NCT05891769 | 99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT(18FCH) | recruiting | Phase 2 / Phase 3 | 100 | Andrei IagaruOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07590024 | RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma(RAIRI-NPC) | recruiting | Phase 3 | 651 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05211232 | Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 450 | Sun Yat-sen UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05145660 | Optimization of Cervical Nodal CTV for Early and Medium Stage NPC | active not recruiting | Phase 3 | 414 | Yi JunlinOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT06277050 | Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma | recruiting | Phase 3 | 264 | Jiangxi Provincial Cancer HospitalOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04436965 | Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition | recruiting | Phase 3 | 266 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05340491 | Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial | recruiting | Phase 3 | 212 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05780372 | Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 474 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05941741 | IC Plus Low-dose Radiation Plus Cadonilimab in LANPC | recruiting | Phase 3 | 380 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05294172 | KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 295 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT01398085 | IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients(IoN) | active not recruiting | Phase 2 / Phase 3 | 504 | University College, LondonOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT02973386 | Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients | completed | Phase 3 | 294 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT03907826 | PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients | recruiting | Phase 3 | 212 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04116047 | CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)(CompARE) | active not recruiting | Phase 3 | 785 | University of BirminghamOTHER | 2 | May 7, 2026 | clinicaltrials |
| NCT07311772 | Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid | recruiting | Phase 3 | 386 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04944914 | Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma | recruiting | Phase 3 | 188 | Sun Yat-sen UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT02633202 | Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era | completed | Phase 3 | 338 | Sun Yat-sen UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
Data updated 11 hours agoSource updated Sep 29, 2026source: clinicaltrials